Renal Diagnostics and Therapeutics Unit, National Institutes of Health, Bethesda, Maryland 20892-1268, USA.
Kidney Int. 2011 Dec;80(11):1198-211. doi: 10.1038/ki.2011.261. Epub 2011 Aug 10.
We have shown that folate-induced kidney dysfunction and interstitial fibrosis predisposes mice to sepsis mortality. Agents that increase survival in normal septic mice were ineffective in a two-stage kidney disease model. Here we used the 5/6 nephrectomy mouse model of progressive chronic kidney disease (CKD) to study how CKD affects acute kidney injury (AKI) induced by sepsis. We induced sepsis using cecal ligation and puncture and found that the presence of CKD intensified the severity of kidney and liver injury, cytokine release, and splenic apoptosis. Accumulation of High Mobility Group Box Protein-1 (HMGB1; a late proinflammatory cytokine released from apoptotic cells), vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-α, interleukin (IL)-6, or IL-10 was increased in CKD or sepsis alone and to a greater extent in CKD-sepsis. Only part of the increase was explained by decreased renal clearance. Surprisingly, we found splenic apoptosis in CKD, even in the absence of sepsis. Although VEGF neutralization with soluble fms-like tyrosine kinase 1 (sFLT-1) (a soluble VEGF receptor) effectively treated sepsis, it was ineffective against CKD-sepsis. A single dose of HMGB1-neutralizing antiserum administered 6 h after sepsis alone was ineffective; however, CKD-sepsis was attenuated by anti-HMGB1. Splenectomy transiently decreased circulating HMGB1 levels, reversing the effectiveness of anti-HMGB1 treatment on CKD-sepsis. Thus, progressive CKD increases the severity of sepsis, in part, by reducing the renal clearance of several cytokines. CKD-induced splenic apoptosis and HMGB1 release could be important common mediators for both CKD and sepsis.
我们已经证明,叶酸诱导的肾功能障碍和间质纤维化使小鼠易发生脓毒症死亡。在两阶段肾病模型中,增加正常脓毒症小鼠存活率的药物无效。在这里,我们使用 5/6 肾切除术小鼠进行进行性慢性肾脏病 (CKD) 模型来研究 CKD 如何影响脓毒症引起的急性肾损伤 (AKI)。我们使用盲肠结扎和穿刺来诱导脓毒症,发现 CKD 的存在加剧了肾脏和肝脏损伤、细胞因子释放和脾细胞凋亡的严重程度。HMGB1(一种来自凋亡细胞的晚期促炎细胞因子)、血管内皮生长因子 (VEGF)、肿瘤坏死因子 (TNF)-α、白细胞介素 (IL)-6 或 IL-10 在 CKD 或脓毒症中单独存在时会增加,并且在 CKD-脓毒症中增加的程度更大。只有部分增加可以通过肾脏清除率降低来解释。令人惊讶的是,我们甚至在没有脓毒症的情况下在 CKD 中发现了脾细胞凋亡。虽然用可溶性 fms 样酪氨酸激酶 1 (sFLT-1)(一种可溶性 VEGF 受体)中和 VEGF 有效治疗了脓毒症,但对 CKD-脓毒症无效。单独在脓毒症后 6 小时给予单次剂量的 HMGB1 中和抗血清无效;然而,CKD-脓毒症通过抗 HMGB1 得到缓解。脾切除术会短暂降低循环 HMGB1 水平,从而逆转抗 HMGB1 治疗对 CKD-脓毒症的效果。因此,进行性 CKD 通过降低几种细胞因子的肾脏清除率,在一定程度上增加了脓毒症的严重程度。CKD 诱导的脾细胞凋亡和 HMGB1 释放可能是 CKD 和脓毒症的重要共同介质。